FGF21 and metabolic dysfunction-associated steatotic liver disease: The association between FGF21 and NAFLD has been confirmed among 3634 participants free of apparent CVD 177, and FGF21 is becoming a potential biomarker to reflect many pathological processes of NAFLD, such as liver fat content and liver inflammation.